Spannella F, Giulietti F, Filipponi A, et al. - Across randomized controlled trials (RCTs) comparing sacubitril/valsartan with renin–angiotensin system (RAS) inhibitors in patients with or without heart failure (HF), the consistency of effect size regarding renal outcome was evaluated via a systematic review and meta‐analysis. Medline (PubMed), Scopus, and Thomson Reuters Web of Science databases were explored. This analysis involved 10 RCTs (published between 2012 and 2019) with 16,456 persons. A lower risk of renal dysfunction was reported in relation to treatment with sacubitril/valsartan vs RAS inhibitors alone, with a moderate inconsistency between studies. With different comparators, no change in the effect size was observed. In this study, sacubitril/valsartan was shown to have a role on preservation of renal function, particularly in older patients and HF patients with preserved ejection fraction. However, evidence is currently restricted to HF patients.